EPM2AIP1 Immunohistochemistry can be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EPM2AIP1 Immunohistochemistry can be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer

Published:2021-11-15 Issue: Volume:Publish Ahead of Print Page:
ISSN:0147-5185
Container-title:American Journal of Surgical Pathology
language:en
Short-container-title:

Author:

Mrkonjic Miralem,Turashvili Gulisa

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EPM2AIP1 immunohistochemistry is inadequate as a surrogate marker for MLH1 promoter hypermethylation testing in colorectal cancer;Human Pathology;2024-08

2. Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers;Journal of Gynecologic Oncology;2024

3. Molecular features for timely cancer diagnosis and treatment – tumors of the ovary, fallopian tube and endometrium;Virchows Archiv;2023-12-15

4. MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal;Cancers;2023-10-28

5. MSI-XGNN: an explainable GNN computational framework integrating transcription- and methylation-level biomarkers for microsatellite instability detection;Briefings in Bioinformatics;2023-09-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP